Arcus’s Casdatifan Could Rival Merck’s Welireg In Clear-Cell RCC
Data from the ARC-20 platform study drive optimism for the Phase III program as the company touts favorable efficacy numbers compared with Merck’s fellow HIF-2? inhibitor.
Scrip - October 20, 2026

All In On ADCs: Drug Developers Shift Attention To The Next Generation
Oncology leaders say they’ve learned how to better design and differentiate newer versions of antibody-drug conjugates following several high-profile setbacks in the field.
Scrip - October 20, 2026

Resmed Partners With Consumer Sleep-Tech Firm Eight Sleep, Launches New Fabric Mask
Resmed is linking Eight Sleep users who show signs of disturbed sleep to a Resmed sleep apnea evaluation, Chief Medical Officer Carlos Nunez said in an interview. The company also plans to launch its AirTouch F40 fabric mask at the end of October.
Medtech Insight - October 20, 2026

GSK’s Jemperli Approved In Rectal Cancer, Thanks To Investigator Study And Novel Endpoint
The PD-1 blocking immunotherapy is the first approved treatment in a subset of rectal cancer patients, building on one oncologist’s drive to help patients and a highly novel trial endpoint.
Scrip - October 20, 2026

AstraZeneca Extends AI Pacts To Clinical Trials With Oracle Tie Up
Unlike a recent AI deal last week focused on drug discovery, AstraZeneca’s non-binding agreement with Oracle targets clinical trials, including patient recruitment.
Scrip - October 20, 2026

Digital Health Roundup: BD’s $19Bn Tariff Deal, AI’s Trust Question, GLP-1 Tools Chasing Proof
In this week's Digital Health Roundup, BD has struck a $19bn US investment deal for relief from future Section 232 tariffs. UltraSight raises $24m for AI echocardiography, Elixir readies a Japan launch, and Reset Health reports GLP-1 adherence data as it courts NICE.
Medtech Insight - October 20, 2026

Strategic Intent: Can Blood Tests Break the Alzheimer’s Diagnosis Bottleneck?
In this episode of Strategic Intent, Dr. Soeren Mattke explains how FDA-cleared p-tau217 blood tests could ease Alzheimer’s diagnostic bottlenecks, while cautioning against screening asymptomatic people.
In Vivo - October 20, 2026

US Industry Rallies To Meet Rising Demand For Estrogen Patches
The US Association for Accessible Medicines has highlighted the crucial role generic medicines manufacturers are playing in the supply of estrogen patches, for which demand has soared.
Generics Bulletin - October 20, 2026

Ambrose Adopts Results-Driven Model To Acquire AM-Pharma
The UK company is buying the Netherlands-based biotech that was once coveted by Pfizer for what could prove to be a bargain.
Scrip - October 20, 2026

Nyxoid: Don’t Put Up Pharmacy Access Barriers, Urges Switch Expert Prof. Brass
EMA supports dropping the prescription requirement for Mundipharma’s Nyxoid, but each EU state will decide where it is sold. Eric Brass, former chair of FDA’s Nonprescription Drugs Advisory Committee, warns that routing OTC naloxone through a pharmacist would replace one access barrier with another.
HBW Insight - October 20, 2026

MHRA Will ‘Routinely’ Use AI And International Reliance In Assessments By 2030
The UK wants to change the way medtech companies interact with its medical regulator via a more transparent process and greater international collaborations.
Medtech Insight - October 20, 2026

Stock Watch: J&J’s Pharma Strength Has Its Limits
Analysts and the press rounded on weak medical device sales in J&J’s third-quarter results, but a deeper dive into its drugs division raised the specters of indication saturation and transient M&A benefits.
Scrip - October 20, 2026

Amneal Defends Parkinson’s Franchise: Crexont Case Dropped By Sandoz, Rytary Antitrust Suit Advances
A Sandoz patent challenge to Amneal’s Crexont has been voluntarily dismissed without prejudice, but an Alembic suit heads to trial in June 2028. Meanwhile, Rytary faces a separate antitrust class action alleging a suppression of generic competition through an authorized generic deal with Zydus.
Generics Bulletin - October 20, 2026

Teva Pushes Back On ‘Politicization’ Of Medicines As UK Organizations Cut Ties
After the UK’s Royal College of Nursing and Royal College of Pharmacy cut ties with Teva, the firm has pushed back by arguing that “healthcare is at its best when it remains focused on patients rather than being politicized.”
Generics Bulletin - October 20, 2026

Precision Oncology Is Booming, But The Main Routes Are Jammed
Everyone in precision oncology is on the same road. Five targets hold 68% of 511 trials, so the real opportunity lies off the beaten track: novel targets, KRAS beyond G12C and niche subpopulations.
In Vivo - October 20, 2026

Baylink Leverages Claudin 6/9 For Global-First Dual-Targeting ADC Push
Taking aim at both ovarian and lung cancers, China and US-based Baylink is stepping into the arena of antibody-drug conjugates on the back of the unique design of a Claudin-targeting asset, its China president tells Scrip.
Scrip - October 20, 2026